Multi-centric Castleman's Disease clinical trials
The registry lists 24 studies for Multi-centric Castleman's Disease across more than 10 countries. 6 are recruiting or about to start. 11 of them are mainly about Multi-centric Castleman's Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-02.
Get an email when these change. Save the Multi-centric Castleman's Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (7) · Peking Union Medical College Hospital (3) · University of Pennsylvania (3) · AIDS Malignancy Consortium (2) · Janssen Research & Development, LLC (2) · Beijing VDJBio Co., LTD. (1) · Castleman Disease Collaborative Network (1) · Recordati UK (1)
What is being tested here
Drugs under test in Multi-centric Castleman's Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Daratumumab | 1 | 0 | 1 |
| Rituximab | 0 | 0 | 3 |
| Cyclophosphamide | 0 | 0 | 3 |
| Siltuximab | 0 | 0 | 3 |
| Liposomal doxorubicin | 0 | 0 | 2 |
| Doxorubicin | 0 | 0 | 2 |
| Bortezomib | 0 | 0 | 2 |
| Prednisone | 0 | 0 | 2 |
| Sirolimus | 0 | 0 | 2 |
| Pomalidomide | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Jun 2027Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease · Phase 3 · Beijing VDJBio Co., LTD.
- Sep 2027International Registry for Patients With Castleman Disease · University of Pennsylvania
Who these studies take
Of the 5 Multi-centric Castleman's Disease studies recruiting now, 3 (60%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (20%) | 1 (20%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 24 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 25% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman DiseaseOct 13, 2026NCT07872423
Studies
Recruiting first, then most recently updated. Showing 24 of 24. search them.
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruitingNCT000065181 country
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingNCT05907759Phase 21 country
- Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman DiseaseRecruitingNCT07872423Phase 31 country
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersRecruitingNCT056635021 country
- International Registry for Patients With Castleman DiseaseRecruitingNCT028179971 country
- Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)Not yet recruitingNCT05995834
- Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 11 country
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 21 country
- Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal AnalysisActive, not recruitingNCT047423871 country
- Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseActive, not recruitingNCT03933904Phase 21 country
- Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiCompletedNCT04585893Phase 21 country
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 11 country
- Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseaseTerminatedNCT04838860Phase 21 country
- Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm TrialStatus unknownNCT04743687Phase 21 country
- Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedNCT01441063Phase 21 country
- Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical TrialsCompletedNCT006954221 country
- TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot TrialStatus unknownNCT03043105Phase 21 country
- Unlock the Cell: Castleman's Disease Flow Cytometry StudyCompletedNCT028539681 country
- BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Status unknownNCT03982771Phase 21 country
- Castleman Disease Collaborative Network BiobankWithdrawnNCT028710501 country
- A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's DiseaseCompletedNCT01400503Phase 217 countries
- A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's DiseaseCompletedNCT01024036Phase 223 countries
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 11 country
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 21 country